Literature DB >> 9646101

[Cytomegalovirus and herpes simplex virus in pathogenesis and progression of native arteriosclerosis and recurrent stenosis after intervention].

M Herzum1, J R Schaefer, G Hufnagel, B Maisch.   

Abstract

An increasing number of clinical and experimental studies point to a contribution of various infectious organisms like chlamydia pneumoniae or herpesviruses to atherosclerosis in man. Cytomegalovirus induces atherosclerotic lesions in animals. In vitro studies reveal functional changes of endothelial cells after infection with cytomegalovirus. Infection with this virus renders endothelial cells immunogenic for cellular and humoral immune reactions. In man a significant association of infections with herpesviruses and atherosclerosis could be established in several studies. Cytomegalovirus infection has been incriminated as an independent risk factor in restenosis after coronary angioplasty.

Entities:  

Mesh:

Year:  1998        PMID: 9646101     DOI: 10.1007/bf03044605

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  40 in total

1.  Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein. Possible mechanisms for activating virus delivered by monocytes to sites of vascular injury.

Authors:  E Guetta; V Guetta; T Shibutani; S E Epstein
Journal:  Circ Res       Date:  1997-07       Impact factor: 17.367

2.  Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells.

Authors:  Y F Zhou; E Guetta; Z X Yu; T Finkel; S E Epstein
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy.

Authors:  Y F Zhou; M B Leon; M A Waclawiw; J J Popma; Z X Yu; T Finkel; S E Epstein
Journal:  N Engl J Med       Date:  1996-08-29       Impact factor: 91.245

Review 4.  Insights into the pathophysiology of unstable coronary artery disease.

Authors:  S D Kristensen; H B Ravn; E Falk
Journal:  Am J Cardiol       Date:  1997-09-04       Impact factor: 2.778

5.  Active cytomegalovirus infection of arterial smooth muscle cells in immunocompromised rats. A clue to herpesvirus-associated atherogenesis?

Authors:  M C Persoons; M J Daemen; J H Bruning; C A Bruggeman
Journal:  Circ Res       Date:  1994-08       Impact factor: 17.367

6.  The procoagulant response of cytomegalovirus infected endothelial cells.

Authors:  M C van Dam-Mieras; A D Muller; V W van Hinsbergh; W J Mullers; P H Bomans; C A Bruggeman
Journal:  Thromb Haemost       Date:  1992-09-07       Impact factor: 5.249

7.  Herpes simplex virus type I does not require productive infection to induce tissue factor in human umbilical vein endothelial cells.

Authors:  N S Key; R R Bach; G M Vercellotti; C F Moldow
Journal:  Lab Invest       Date:  1993-06       Impact factor: 5.662

8.  Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).

Authors:  J Kjekshus; T R Pedersen
Journal:  Am J Cardiol       Date:  1995-09-28       Impact factor: 2.778

9.  Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.

Authors:  P Saikku; M Leinonen; L Tenkanen; E Linnanmäki; M R Ekman; V Manninen; M Mänttäri; M H Frick; J K Huttunen
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  1 in total

Review 1.  Microorganisms in the aetiology of atherosclerosis.

Authors:  S A Morré; W Stooker; W K Lagrand; A J van den Brule; H W Niessen
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.